



The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease



Myeong Jun Song^{a,b}, Harmeet Malhi^{a,*}

^a Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, United States of America

^b Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

ARTICLE INFO

Available online 13 August 2019

Keywords:

Nonalcoholic steatohepatitis
Lipotoxicity
Endoplasmic reticulum stress
Palmitate
Sphingolipids

ABSTRACT

Nonalcoholic fatty liver disease is a major public health burden. Although many features of nonalcoholic fatty liver disease pathogenesis are known, the specific mechanisms and susceptibilities that determine an individual's risk of developing nonalcoholic steatohepatitis versus isolated steatosis are not well delineated. The predominant and defining histologic and imaging characteristic of nonalcoholic fatty liver disease is the accumulation of lipids. Dysregulation of lipid homeostasis in hepatocytes leads to transient generation or accumulation of toxic lipids that result in endoplasmic reticulum (ER) stress with inflammation, hepatocellular damage, and apoptosis. ER stress activates the unfolded protein response (UPR) which is classically viewed as an adaptive pathway to maintain protein folding homeostasis. Recent studies have uncovered the contribution of the UPR sensors in the regulation of hepatic steatosis and in the cellular response to lipotoxic stress. Interestingly, the UPR sensors can be directly activated by toxic lipids, independently of the accumulation of misfolded proteins, termed lipotoxic and proteotoxic stress, respectively. The dual function of the UPR sensors in protein and lipid homeostasis suggests that these two types of stress are interconnected likely due to the central role of the ER in protein folding and trafficking and lipid biosynthesis and trafficking, such that perturbations in either impact the function of the ER and activate the UPR sensors in an effort to restore homeostasis. The precise molecular similarities and differences between proteotoxic and lipotoxic ER stress are beginning to be understood. Herein, we provide an overview of the mechanisms involved in the activation and cross-talk between the UPR sensors, hepatic lipid metabolism, and lipotoxic stress, and discuss the possible therapeutic potential of targeting the UPR in nonalcoholic fatty liver disease.

© 2019 Published by Elsevier Inc.

Contents

1. Introduction	2
2. Unfolded protein response	2
3. Hepatic lipid metabolism	3
4. Unfolded protein response and hepatic lipid metabolism	3
5. Lipotoxic ER stress	4
6. Therapeutic potential targeting ER stress and UPR in NAFLD	6
7. Conclusions	7
References	8

Abbreviations: ACC, acetyl-CoA carboxylase; ATF, activating transcription factor; ApoB, apolipoprotein B; BI-1, Bax Inhibitor 1; BH, Bcl-2 homology; BiP, binding immunoglobulin protein; C/EBP, CCAAT/enhancer-binding protein; CHOP, CCAAT-enhancer-binding protein homologous protein; ER, endoplasmic reticulum; ERAD, ER-associated degradation; eIF2 α , eukaryotic translation initiation factor 2 α ; FA, fatty acid; FGF21, fibroblast growth factor 21; GADD34, growth arrest and DNA damage-inducible protein; HFD, high fat diet; IRE, inositol-requiring enzyme; INSIG, insulin-induced gene; JNK, c-Jun N-terminal kinase; LPC, lysophosphatidylcholine; MTP, microsomal TG transfer protein; NAFLD, Nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; 4-PBA, 4-phenylbutyric acid; PC, phosphatidylcholine; PERK, protein kinase RNA-like ER kinase; PLA2, phospholipase A2; PPAR, peroxisome proliferator-activated receptor; PUMA, p53 upregulated modulator of apoptosis; RIDD, regulated IRE1 α -dependent decay; RNase, endoribonuclease; SCAP, SREBP cleavage-activating protein; SCD, stearoyl-CoA desaturase; SFA, saturated fatty acid; S1P, site 1 protease; S2P, site 2 protease; SP1P, sphingosine 1-phosphate; SREBP, sterol regulatory element binding proteins; TG, triglyceride; TUDCA, tauroursodeoxycholic acid; UPR, unfolded protein response; VLDL, very low density lipoprotein; XBP1, X-box binding protein 1.

* Corresponding author at: Medicine and Physiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States of America.

E-mail address: Malhi.harmeet@mayo.edu (H. Malhi).

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is currently the leading cause of chronic liver disease and estimated to affect approximately 30% of the U.S population (Satapathy & Sanyal, 2015; Younossi et al., 2019). NAFLD is a heterogeneous disease ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) with or without hepatic fibrosis. Its prevalence in specific groups, such as patients with type 2 diabetes or morbid obesity is even higher, occurring in roughly 60 and 80% of these individuals, respectively (Amor & Perea, 2019; Blond et al., 2017; Younossi et al., 2019). NAFLD is characterized by the accumulation of various lipid species within hepatocytes (Marra & Svegliati-Baroni, 2018). The lipids that can activate and induce progressive liver injury are defined as toxic lipids in NASH pathogenesis. In general, the saturated fatty acids (SFAs) such as palmitate, ceramides, lysophosphatidylcholine (LPC), and free cholesterol are directly cytotoxic, whereas the monounsaturated free fatty acids, such as oleate and palmitoleate, may protect from SFA-induced toxicity (Akazawa et al., 2010; Hirsova, Ibrahim, Gores, & Malhi, 2016; Malhi, Barreiro, Isomoto, Bronk, & Gores, 2007; Malhi, Bronk, Werneburg, & Gores, 2006). The consequent hepatocellular damage characterized by inflammation and hepatocellular apoptosis is linked to dysfunction of the endoplasmic reticulum (ER), resulting from toxic lipids termed as lipotoxic ER stress or lipid bilayer stress (Pagliassotti, 2012; Volmer, van der Ploeg, & Ron, 2013). Lipotoxic ER stress appears to follow a continuum that progresses from non-lethal or sub-lethal responses to ER stress-induced cell death. Lipotoxic ER stress may also be proinflammatory as we have recently demonstrated that lipotoxic sublethal ER stress response leads to the release of proinflammatory extracellular vesicles (Kakazu, Mauer, Yin, & Malhi, 2016). Steatosis and ER stress are also features of alcoholic hepatitis and ER stress is now accepted as an important mechanism in alcoholic hepatitis pathogenesis and progression (Joshi-Barve, Kirpich, Cave, Marsano, & McClain, 2015; Masouminia et al., 2016). The role of ER stress in alcoholic hepatitis is reviewed elsewhere in detail (Ji, 2014; Joshi-Barve et al., 2015; Masouminia et al., 2016). This review focuses on the UPR in lipid metabolism and NAFLD. We review the signaling pathways mediated by the canonical UPR, how the UPR sensors contribute to and respond to perturbation in hepatic lipid homeostasis under ER stress or independently, and lipotoxic ER stress. Lastly, we discuss the therapeutic potential of targeting the UPR in NAFLD.

2. Unfolded protein response

The ER is an essential subcellular compartment responsible for the synthesis and folding of proteins that traffic through the secretory pathway in the cell. Protein folding is sensitive to alterations in ER homeostasis including Ca^{2+} levels, energy and nutrient availability, as well as the protein-folding load in the ER (S. Wang & Kaufman, 2014) (Walter & Ron, 2011). Perturbations in these pathways interfere with protein folding in the ER leading to proteotoxic ER stress, which in turn activates the UPR. The UPR is initially an adaptive signaling pathway which aims to elicit global cellular changes such as attenuation of translation and activates specific pathways of protein folding and degradation to restore ER homeostasis (S. Wang & Kaufman, 2012). When ER homeostasis cannot be restored ER stress-induced apoptosis occurs. Canonically, the UPR is activated via the luminal domains of three principal transmembrane sensors: inositol-requiring enzyme (IRE)-1 α , protein kinase RNA-like ER kinase (PERK), and activating transcription factor (ATF)-6 α .

2.1. IRE1 α pathway

The IRE1 α pathway is the most conserved arm of the UPR. IRE1 α is a ubiquitously expressed transmembrane protein that possesses dual enzymatic activities of serine/threonine kinase and endoribonuclease

(RNase) on its cytosolic domain (Lebeaupin et al., 2018). In the physiologic state, the luminal domain of IRE1 α is bound by the ER chaperone binding immunoglobulin protein (BiP) and remains inactive. In response to the accumulation of unfolded proteins, BiP releases IRE1 α allowing its activation by dimerization and autophosphorylation via kinase activity, inducing a conformational change that activates the RNase activity. Alternatively, unfolded proteins may directly bind to the luminal domain of IRE1 α , inducing allosteric changes that trigger its activation (Karagoz et al., 2017). Activated IRE1 α induces unconventional (cytosolic) excision of 26 nucleotides from the mRNA encoding X-box binding protein 1 (XBP1) to generate spliced XBP1. Spliced XBP1 is a transcription factor which upregulates the expression of several ER chaperones to increase protein folding capacity and also ER-associated degradation (ERAD). In irremediable ER stress, IRE1 α RNase activity becomes promiscuous, leading to degradation of many other ER-bound mRNAs and microRNAs through regulated IRE1 α -dependent decay (RIDD) (D. Han et al., 2009; Hollien et al., 2009; Hollien & Weissman, 2006). Enhanced RIDD leads to pro-apoptotic signaling by rapid decay of select microRNAs that normally repress the pro-apoptotic pathway (Upton et al., 2012). Activated IRE1 α also recruits tumor necrosis factor receptor-associated factor 2 leading to activation of the c-Jun N-terminal kinase (JNK) via apoptosis-signal-regulating kinase 1 and the activation of nuclear factor κ B (NF κ B) (Hu, Han, Couvillon, Kaufman, & Exton, 2006; Tam, Mercado, Hoffmann, & Niwa, 2012; Urano et al., 2000). JNK promotes apoptosis via Bcl-2 homology (BH) 3-only proteins and the Bax/Bak-dependent mitochondrial apoptotic machinery.

2.2. PERK pathway

PERK is a transmembrane protein with an N-terminal stress-sensing domain and a cytosolic kinase domain. Similar to IRE1 α , the luminal domain of inactive PERK is bound to BiP (Bertolotti, Zhang, Hendershot, Harding, & Ron, 2000). PERK activation relies on dimerization and tetramerization mediated via its luminal domain leading to autophosphorylation upon the sensing of unfolded proteins (Carrara, Prisci, Nowak, & Ali, 2015). After activation, PERK phosphorylates eukaryotic translation initiation factor 2 α (eIF2 α) (N. Donnelly, Gorman, Gupta, & Samali, 2013). To attenuate overall protein overload, phosphorylated eIF2 α holds back mRNA translation preventing 80S ribosome assembly, except for select mRNAs including the transcription factor ATF4 (Blais et al., 2004; Harding, Zhang, & Ron, 1999). ATF4 then activates the transcription of specific UPR target genes, such as CCAAT-enhancer-binding protein homologous protein (CHOP) and the growth arrest and DNA damage-inducible protein (GADD34). CHOP is a transcription factor that triggers cell death by inducing genes involved in apoptosis in the presence of ER stress (Nishitoh, 2012) and may also promote ER stress-induced cell death by premature translational recovery (J. Han et al., 2013). In contrast, GADD34 forms a feedback loop by dephosphorylation of eIF2 α and recovery from translational inhibition in the UPR (Novoa, Zeng, Harding, & Ron, 2001).

2.3. ATF6 α pathway

ATF6 α is a type II ER transmembrane protein with a cytosolic bZip transcription factor domain and specialized in the regulation of ER quality control proteins (Adachi et al., 2008). Upon proteotoxic ER stress, ATF6 α is packed into coat protein complex II vesicles and transported to the Golgi (Schindler & Schekman, 2009). In the Golgi apparatus it is cleaved by site-1 protease (S1P) and site-2 protease (S2P), releasing a 50 kDa cytosolic fragment that migrates to the nucleus, and is referred to as ATF6N or ATF6F. Though the activation of ATF6 α in the Golgi is similar to SREBPs (discussed below), the proximal pathways that mediate translocation of ATF6 α or SREBPs to the Golgi are distinct. ATF6 α is activated by the accumulation of unfolded proteins and SREBPs are regulated by sterols (Haze, Yoshida, Yanagi, Yura, & Mori, 1999; Horton, Goldstein, & Brown, 2002). Cleaved ATF6 α activates UPR target genes

including ERAD, phospholipid synthesis, and cooperatively the transcription of XBP1 target genes via direct binding to the ER stress response element (Bommiasamy et al., 2009; Ho, Xu, & Thibault, 2018; Wu et al., 2007; Yoshida, Matsui, Yamamoto, Okada, & Mori, 2001). Enforced expression of cleaved ATF6 α can also upregulate cholesterol synthesis (Maruyama, Kamoshida, Shimizu, Inoue, & Sato, 2013).

3. Hepatic lipid metabolism

Lipids are part of the cell structure, and are involved in essential functions such as cellular homeostasis, cell-to-cell communication and regulation of inflammation. The liver plays a predominant role in regulating lipid homeostasis via the major lipid metabolic pathways, including *de novo* lipogenesis which includes fatty acid (FA) synthesis, triglyceride (TG) synthesis and storage, synthesis of complex lipids such as cholesterol, ceramide and phospholipid, lipoprotein synthesis and secretion, lipolysis and FA oxidation (Simha & Garg, 2006; S. Wang & Kaufman, 2014). Many of these functions are housed in the ER, especially *de novo* ceramide biosynthesis, cholesterol synthesis, lipid droplet formation and export of TG as very low density lipoprotein (VLDL) (Fagone & Jackowski, 2009).

3.1. De Novo lipogenesis

Hepatic *de novo* lipogenesis is regulated by ER membrane-bound transcription factors, the sterol regulatory element binding proteins (SREBPs), SREBP-1a, SREBP-1c, and SREBP-2, of which SREBP-1c and SREBP-2 are predominantly expressed in the liver (Brown & Goldstein, 1997; Eberle, Hegarty, Bossard, Ferre, & Foufelle, 2004; Horton et al., 2002). SREBP-1c controls FA and TG biosynthesis, while SREBP-2 controls cholesterol metabolism and low density lipoprotein receptor expression (Hinz, Giebel, & Campos-Ortega, 1994; Yokoyama et al., 1993; Zhou & Liu, 2014). SREBP-1c and SREBP-2 expression can be regulated transcriptionally and post-transcriptionally, comprehensively reviewed elsewhere (Horton et al., 2002). Post-transcriptional processing of SREBPs is suppressed by sterols. SREBP-1c is embedded in the ER membranes bound to the protein SREBP cleavage-activating protein (SCAP). SCAP interacts with the insulin-induced gene (INSIG) protein which retains the complex SREBP-1c/SCAP in the ER. Similar to canonical regulation by sterols and insulin, under ER stress, SCAP dissociates from INSIG and the complex SCAP/SREBP-1c is transferred to the Golgi apparatus in coat protein II vesicles (Kammoun et al., 2009). SREBP-1c undergoes regulated intramembrane proteolysis by S1P and S2P to release a cytosolic transcription factor that traffics to the nucleus to induce the expression of genes involved in *de novo* FA synthesis including acetyl-CoA carboxylase (ACC), FA synthase, the long-chain elongase and stearoyl-CoA desaturase (SCD) (Brown & Goldstein, 1997; Foufelle & Ferre, 2002; Postic & Girard, 2008; S. Wang & Kaufman, 2014). Cleavage of SREBP-2 occurs in a manner similar to SREBP-1c via dissociation of INSIG from SREBP-2/SCAP leading to transcriptional upregulation of cholesterol biosynthetic genes (Dong, Tang, & Chen, 2012; Sakakura et al., 2001).

3.2. Hepatic lipid storage in the form of TGs

The hallmark of NAFLD is the accumulation of fat in the hepatocytes, in the form of lipid droplets containing TG (Marra & Svegliati-Baroni, 2018). TGs are synthesized from FAs and glycerol by a group of ER-localized acyltransferase enzymes including glycerol-3-phosphate acyltransferase, acylglycerolphosphate acyltransferase, monoacylglycerol acyltransferase or diacylglycerol acyltransferase (Gimeno & Cao, 2008; Liu, Siloto, Lehner, Stone, & Weselake, 2012). The majority of TG produced by the ER further drives the synthesis of lipid droplets, which originate from the ER membrane and form phospholipid monolayer enclosed droplet structures containing a high abundance of hydrophobic TGs, cholesterol ester and droplet structural proteins. Lipid

droplets composed of TGs and cholesterol esters serve as a storage reservoir to prevent toxic accumulation of free FAs and cholesterol (Olofsson et al., 2008; Reue, 2011). In addition, membrane phospholipids including phosphatidylcholine and phosphatidylethanolamine are synthesized via ER-localized enzymes, including the diacylglycerol choline/ethanolaminophosphotransferases (Fagone & Jackowski, 2009; Lagace & Ridgway, 2013).

3.3. Export of TG as VLDL

TGs are secreted from the liver in the form of VLDL through the fusion of apolipoprotein B-100 (Cohen & Fisher, 2013). VLDL synthesis is initiated by co-translational translocation of apolipoprotein B (ApoB) into the ER lumen for assembly with bulk neutral lipids, especially TGs (Tiwari & Siddiqi, 2012). The microsomal TG transfer protein (MTP) protein complex, composed of MTP and protein disulfide isomerase 1, is thought to play a critical role in facilitating the accretion of TGs into the ER lumen for ApoB lipidation and prevent intrahepatic TG accumulation (Hussain, Shi, & Dreizen, 2003). VLDL assembly and secretion are complex processes involving an array of protein and lipid factors (Rutledge, Su, & Adeli, 2010). A significant portion of ER chaperone proteins were found to be associated with ApoB, which could either promote ApoB folding and lipidation or mediate ApoB co-translational or post-translational degradation (Olofsson & Boren, 2012). Overproduction of hepatic VLDL particles can cause dyslipidemia, which is frequently observed in NAFLD and tightly associated with an increased risk of cardiovascular disease in obese patients with type 2 diabetes and NAFLD (Hassing et al., 2012). Thus, the ER in hepatocytes not only plays an important role in intrahepatic lipid homeostasis, but is also tightly linked to circulating lipid homeostasis.

4. Unfolded protein response and hepatic lipid metabolism

Protein misfolding in the ER with associated ER stress causes hepatic steatosis, which is observed in mice with genetic ablation of the UPR sensors (Rutkowski et al., 2008). ER stress-induced hepatic steatosis is multifactorial and can occur via the regulation of lipogenesis, VLDL secretion, and FA oxidation. Not only is steatosis observed in response to ER stress, recent studies have demonstrated that the UPR sensors directly play a role in the regulation of lipid metabolism, and lipotoxicity can activate an ER stress response, as discussed below. Overall, the interplay between UPR sensors and hepatic lipid metabolism is complex and likely only partially understood.

4.1. IRE1 α /XBP1 pathway

IRE1 α is a key regulator of hepatic lipid homeostasis through repressing hepatic lipid accumulation and maintaining lipoprotein secretion. Under ER stress with chemical inducing agent, mice with hepatocyte-specific deletion of IRE1 α developed hepatic steatosis and increased expression of several transcriptional genes involved in lipid metabolism, including *CCAAT/enhancer-binding protein (C/EBP)* β , *C/EBP* δ , *peroxisome proliferator-activated receptor (PPAR)* γ , and enzymes involved in TG biosynthesis pointing to increased *de novo* lipogenesis (Zhang et al., 2011). On the other hand, in the genetic absence of *Ire1 α* in hepatocytes, under basal conditions there was reduced protein disulfide isomerase, which acts with MTP to promote the delivery of neutral lipids to the smooth ER lumen for VLDL assembly (S. Wang et al., 2012). Thus, hepatocyte-specific *Ire1 α* deletion did not alter lipogenesis, but rather, specifically impaired VLDL assembly and secretion, leading to steatosis (Wang et al., 2012; Zhang et al., 2011). In addition, experimental manipulation of XBP1, a downstream transcription factor of IRE1 α , highlighted a critical role for IRE1 α in lipid metabolism. Hepatic deletion of *Xbp1* decreased *de novo* hepatic lipogenesis, leading to reduced serum TG, cholesterol, and free FAs by regulation of lipogenic genes including *diacylglycerol acyltransferase 2*, *Scd1*, and *Acc2* (Lee, Scapa,

Cohen, & Glimcher, 2008). Later studies demonstrated that *Xbp1* deletion triggers feedback hyperactivation of IRE1 α , inducing RIDD of cytosolic mRNAs encoding lipid metabolism functions, thereby reducing plasma TG and cholesterol in these mice (So et al., 2012). IRE1 α is also a target for inflammatory signaling as recently demonstrated via inducible nitric oxide synthase mediated nitrosylation of IRE1 α which results in a reduction in IRE1 α mediated *Xbp1* splicing and impaired glucose homeostasis (Yang et al., 2015), and impaired degradation of microRNAs which repress PPAR α and the deacetylase sirtuin 1, thus decreasing FA oxidation and lipolysis (Wang et al., 2018). Elevated plasma VLDL is a component of the dyslipidemia commonly observed in obesity-associated NAFLD. It is possible that IRE1 α activation leads to increased rates of VLDL secretion in obesity, and thus contributes to dyslipidemia. These studies place IRE1 α in a central position in mitigating hepatic steatosis via repression of lipolysis and export of VLDL.

On the other hand, there is evidence that constraining IRE1 α activity in hepatocytes and in mice impairs inflammasome activation, liver injury, inflammation and hepatocyte apoptosis (Lebeauupin et al., 2018). Recently, it has been demonstrated that IRE1 α activation leads to the release of proinflammatory extracellular vesicles from hepatocytes (Kakazu et al., 2016). Thus inhibition of proinflammatory extracellular vesicle release may be a possible explanation for why inhibition of IRE1 α activation impairs hepatic inflammation. Altogether, observations on the role of IRE1 α in regulation of lipid metabolism point toward IRE1 α -mediated mitigation of steatosis which would suggest that IRE1 α activation might improve hepatic steatosis. However, IRE1 α also promotes inflammation. We propose that the predominant output of IRE1 α activation in the subset of NAFLD that develop progressive hepatic injury and inflammation (NASH) is proinflammatory. The determinants of IRE1 α fates suggest a role for Bax Inhibitor 1 (BI-1), a negative regulator of IRE1 α activation, and the magnitude of RIDD. For example, absence of BI-1 worsens NASH, potentially by hyperactivation of IRE1 α with resultant persistent XBP1 processing and greater RIDD, with activation of the inflammasome, inflammation, and liver injury.

4.2. PERK-eIF2 α pathway

The PERK pathway also regulates hepatic lipid metabolism. Antipsychotic drug-induced PERK and eIF2 α phosphorylation results in increased hepatic steatosis through activation of SREBP-1c and SREBP-2 (Lauresseguies et al., 2012). The eIF2 α phosphorylation resistant knockin mutant mice also showed exacerbation of lipid droplet coat proteins in response to pharmacologic ER stress (Rutkowski et al., 2008). Transgenic mice with compromised eIF2 α phosphorylation by overexpressing GADD34, eIF2 α specific phosphatase, are protected from high-fat diet (HFD)-induced hepatic steatosis (Oyadomari, Harding, Zhang, Oyadomari, & Ron, 2008). ATF4, the downstream effector of the PERK/eIF2 α pathway, is involved in lipid metabolism. *Atf4*^{-/-} mice displayed high-carbohydrate diet induced suppression of SCD1 expression which was protective for hepatic steatosis (Li et al., 2011). *Atf4* depletion also attenuated lipid accumulation accompanied by a significant reduction in hepatic expression of SREBP-1c, ACC, and FA synthase (Xiao et al., 2013).

CHOP is involved in the disruption of FA oxidation and lipoprotein secretion through suppression of C/EBP α (Rutkowski et al., 2008). Under pharmacologic ER stress, deletion of *Chop* in mice showed less suppressed expression of transcriptional regulators, including C/EBP α , PPAR α , SREBP-1, and PPAR gamma coactivator 1 α , compared with wild-type mice. However, though *Chop*^{-/-} mice exhibit greater adiposity basally, they showed reduced expression of lipogenic genes with less lipid accumulation than wild-type mice upon human immunodeficiency virus protease inhibitor (Wang et al., 2013). Therefore, it is necessary to elucidate the exact molecular and cellular mechanisms underlying CHOP-mediated dysregulation of hepatic lipid metabolism.

4.3. ATF6 α pathway

Transcriptional induction of mammalian ER quality control proteins is mediated by combined action of ATF6 α and XBP1 (Yamamoto et al., 2007). ATF6 α stimulates hepatic FA oxidation possibly through interaction with PPAR α . The PPAR α /retinoid X receptor heterodimer may serve as the key functional regulator transducing ATF6 α signaling to the transcription of genes involving hepatic FA oxidation, such as carnitine palmitoyltransferase 1A, medium-chain acyl-coenzyme A dehydrogenase, and fibroblast growth factor 21 (FGF21), via the PPAR response element sequence (Chen et al., 2016). Cleaved ATF6 α binds to sterol regulatory response element-bound SREBP-2 and recruits histone deacetylase 1, thus inhibiting sterol regulatory response element-mediated transcriptional activation and activate genes involved in UPR (Zeng et al., 2004). *Atf6 α* knockout mice accumulated lipids in the liver, due to blockage of β -oxidation of FAs and the suppression of VLDL formation (DeZwaan-McCabe et al., 2017; Yamamoto et al., 2010). When fed a HFD, *Atf6 α* ^{-/-} mice developed hepatic steatosis and glucose intolerance in association with increased expression of SREBP-1c (Usui et al., 2012).

5. Lipotoxic ER stress

Lipotoxicity is defined as dysregulation of the lipid environment and/or intracellular composition leading to the accumulation or transient generation of toxic lipids, which may result in hepatocyte injury or death (Malhi & Gores, 2008). Toxic lipid classes include the following; the SFA palmitate, sphingolipids including C16:0 ceramide, the phospholipid LPC, and free cholesterol (Musso, Cassader, Paschetta, & Gambino, 2018). ER stress is one manifestation of lipotoxicity due to these lipid classes, whereas the monounsaturated free FAs, such as oleate and palmitoleate, may protect from SFA-induced toxicity (Fig. 1) (Akazawa et al., 2010; Malhi et al., 2006; Malhi et al., 2007).

5.1. Palmitate

Palmitate in hepatocytes is converted to palmitoyl-CoA and under excess conditions can be incorporated in to various lipids (Fig. 2). Palmitate can induce the accumulation of ceramide from de novo synthesis at the ER, increase LPC formation via phospholipase A2 (PLA2) action on phosphatidylcholine (PC), which in turn is derived from diacylglycerol (Hirsova et al., 2016). Excess palmitate can also lead to the accumulation of di-saturated glycerolipids in the ER which trigger sustained IRE1 α and PERK activation (Ariyama, Kono, Matsuda, Inoue, & Arai, 2010; Volmer et al., 2013). The increased availability of palmitate by up-regulating ER localized glycerol-3-phosphate acyltransferase can incorporate this FA into membrane lipids (Piccolis et al., 2019). Additionally, in hepatocytes, palmitate can increase the de novo biosynthesis of saturated phospholipids contributing to palmitate-induced lipotoxic ER stress (Leamy et al., 2014). Therefore, homeostatic pathways that maintain membrane lipid saturation during palmitate stress are important to prevent lipotoxicity. Palmitate-induced ER stress can result in apoptosis, such that knockdown of *PERK* gene expression significantly inhibited palmitate-induced apoptosis (Cao et al., 2012). Attenuation of ER stress by BiP overexpression suppressed palmitate-induced cell death through regulation of IRE1 α , phosphorylated eIF2 α and CHOP (Gu et al., 2010). Downstream of persistent UPR activation, palmitate-mediated hepatocyte lipoapoptosis was triggered by JNK activation and CHOP- and JNK-dependent upregulation of the potent proapoptotic BH3-only protein p53 upregulated modulator of apoptosis (PUMA) (Cazanave et al., 2010; Kakisaka et al., 2012).

5.2. Ceramides

Ceramides are members of the sphingolipid family including sphingosine and sphingosine 1-phosphate (SP1P) and are integral to the




Fig. 1. Proteotoxic and lipotoxic unfolded protein response signaling. Proteotoxic stress due to the accumulation of misfolded or unfolded proteins activates the three transmembrane ER stress sensors (IRE1 α , PERK, ATF6) by releasing them from BiP binding or by direct binding of the unfolded proteins to the luminal domain of the UPR sensors. Lipotoxic ER stress due to increased membrane saturation or sphingolipid accumulation is sensed by the transmembrane domains of the UPR sensors. Activated IRE1 α induces splicing of XBP1. Spliced XBP1 transcriptionally upregulates genes that encode protein folding machinery, ERAD genes, and lipid synthesis pathways. PERK phosphorylates eIF2 α which suppress mRNA translation leading to attenuation of protein synthesis. ATF4 is selectively translated and upregulates several transcriptional targets including CHOP. CHOP-dependent apoptosis occurs under unresolved ER stress. ATF6 α translocates from the ER to the Golgi complex and cleaved by S1P and S2P. Cleaved ATF6 α , termed ATF6N, transcriptionally upregulates UPR target genes. Abbreviation: IRE1 α , inositol-requiring enzyme 1; PERK, PKR-like endoplasmic reticulum kinase; ATF6 α , activating transcription factor 6; TRAF2, Tumor necrosis factor receptor-associated factor 2; ASK1, apoptosis-signal-regulating kinase 1; JNK, c-Jun N-terminal kinase; XBP1u, X-box binding protein 1; XBP1s, spliced X-box binding protein 1; RIDD, regulated IRE1 α -dependent decay; eIF2 α , eukaryotic translation initiation factor 2 α ; GADD34, growth arrest and DNA damage-inducible protein; ATF4, activating transcription factor 4; UPR, unfolded protein response; ERAD, endoplasmic reticulum-associated degradation; CHOP, CCAAT-enhancer-binding protein homologous protein; ATF6N, cleaved ATF6; BiP, binding immunoglobulin protein; S1P, site 1 protease; S2P, site 2 protease.

structure of the lipid bilayer that makes up cell membranes (Hannun & Obeid, 2008; Pagadala, Kasumov, McCullough, Zein, & Kirwan, 2012). Ceramides can be synthesized *de novo* from serine and palmitate

by the sequential action of 3 ER resident enzymes (serine palmitoyltransferase, ceramide synthase, and dihydroceramide desaturase) or generated from hydrolysis of plasma membrane




Fig. 2. Palmitate-induced lipotoxicity. Excess palmitate availability to the hepatocyte, derived predominantly from adipose tissue lipolysis in insulin resistance, leads to lipid accumulation and palmitate lipotoxicity. To maintain lipid homeostasis, fatty acid disposal in the liver occurs through the formation of triglyceride which is then stored temporarily as lipid droplets (steatosis) or secreted as VLDL. In hepatocytes, conversion of free fatty acids to triglycerides protects the cells from lipotoxicity; whereas higher levels of SFAs such as palmitate, are lipotoxic. Palmitate can be directly or indirectly metabolized into other lipid classes including ceramides and LPC which contribute to palmitate-induced ER stress. The generation of lipotoxic metabolites of fatty acids typically occurs in parallel with the accumulation of triglyceride droplets (steatosis), resulting in the hallmark features recognized as nonalcoholic steatohepatitis where steatosis and hepatocellular injury are present together. Abbreviation: SFA, saturated fatty acid; DAG, diacylglycerol; PC, phosphatidylcholine; PLA2, phospholipase A2; LPC, lysophosphatidyl choline; SCD1, stearyl-CoA desaturase; TG, triglyceride; VLDL, very low density protein; ER, endoplasmic reticulum.

sphingomyelin into ceramide and phosphocholine by the enzyme sphingomyelinase (Musso et al., 2018). Sphingolipids are necessary to maintain lipid homeostasis and prevent ER stress, although it is unclear how alterations in sphingolipid biosynthesis are sensed by the IRE1 α and PERK (Breslow, 2013). ATF6 α can be activated by specific sphingolipids which are recognized by a motif in its transmembrane domain (Tam et al., 2018). The deletion of Orm1 or Orm2 in yeast, which negatively regulate serine palmitoyltransferase complex in sphingolipid synthesis, led to lipid-mediated UPR activation (Futerman & Riezman, 2005; S. Han, Lone, Schneider, & Chang, 2010; Ho et al., 2018; Jonikas et al., 2009; Liu, Huang, Polu, Schneider, & Chang, 2012). In addition, the accumulation of C16 ceramide induced ER stress by the disturbance in Ca²⁺ homeostasis and led to cell death through the activation of the PERK/ATF4 and ATF6 α arms of the UPR, resulting in the induction of CHOP expression (Aflaki et al., 2012; Epstein et al., 2012; Pettus, Chalfant, & Hannun, 2002).

Ceramides also play a critical role in insulin resistance and regulation of hepatic steatosis. Although the mechanism by which ceramides induce hepatic insulin resistance is not completely understood, ceramide-mediated insulin resistance may be induced through atypical protein kinase C activation and associated lipogenic and lipid uptake processes, while simultaneously impairing Akt-mediated regulation of hepatic glucose output (Ribaux & Iynedjian, 2003; Summers, 2006; Yang et al., 2009). Recent studies show that inhibition of dihydroceramide desaturase 1 in the liver or the adipose tissue was sufficient to restore insulin sensitivity in high fat fed mice. These studies not only identified a potential therapeutic target for the treatment of obesity-associated insulin resistance, but also suggest that ceramides may mediate organ-to-organ crosstalk as deletion of the enzyme in liver alone or adipose tissue alone restored insulin sensitivity (Chaurasia et al., 2019). Experimental models show that ceramide promotes protein kinase C ζ activation as a mediator of SREBP-1c driven lipogenesis and CD36-mediated lipid uptake in the liver (Xia et al., 2015). In HFD mouse, overexpression of sphingosine kinase 1 which promotes the conversion of ceramide to SP1P ameliorates insulin resistance (Bruce et al., 2012). The accumulation of SP1P upon depletion of SP1P-phosphohydrolase triggered ER stress and autophagy (Lepine et al., 2011). Hepatic ceramide accumulation is increased in NAFLD and correlated with disease progression (Gorden et al., 2015). Furthermore, blocking de novo ceramide synthesis reduced fat accumulation and hepatic TG content (G. Yang et al., 2009). Ceramides may also promote inflammation in NASH as palmitate-induced the release of pro-inflammatory extracellular vesicles in an IRE1 α /XBP1-dependent manner via the transcriptional activation of the *de novo* ceramide synthesis pathway (Kakazu et al., 2016). Though ceramide accumulation in the ER is implicated in pancreatic β -cell death (Han & Kaufman, 2016), inhibition of de novo ceramide synthesis did not prevent palmitate-induced ER stress and apoptosis in hepatocytes (Wei, Wang, Topczewski, & Pagliassotti, 2006). Altogether, these data suggest a role for sphingolipid metabolism in maintenance of ER homeostasis and in insulin resistance, hepatic steatosis as well as formation of lipotoxic extracellular vesicles.

5.3. Lysophosphatidylcholine

LPC is a major component of cell membrane bilayers, lipid droplet envelop monolayers, and VLDL (Neuschwander-Tetri, 2010; Wiesner, Leidl, Boettcher, Schmitz, & Liebisch, 2009). LPC is another important phospholipid mediator of SFA induced lipotoxicity in NASH (Han et al., 2008). LPC is generated from PC intracellularly by PLA2 or extracellularly by plasma lecithin-cholesterol acyltransferase (Musso, Gambino, & Cassader, 2009). PLA2 inhibition decreased intracellular LPC and palmitate-induced apoptosis (Donnelly et al., 2005; Kakisaka et al., 2012). An additional important mechanism of lipotoxicity is the depletion of membrane PC caused by PLA2 activation (Li et al., 2006). PC is the most abundant phospholipid and is essential for cell membrane integrity, and is an important feedback inhibitor of SREBP-1c-mediated

lipogenesis (Walker et al., 2011). Hepatocytes have a high demand for PC, which is used for the production and secretion of VLDL. Hepatic PC depletion and perturbation of hepatocyte membrane integrity result in extracellular release of lipotoxic lipids, inflammation, and hepatocyte apoptosis. Similar to palmitate, LPC induces ER stress including phosphorylation of eIF2 α and subsequent increased CHOP expression and JNK activation, resulting in the induction of the BH3-only protein PUMA. Increased PUMA causes subsequent Bax activation, caspase 3/7 activation, and apoptosis (Kakisaka et al., 2012).

5.4. Interconnectedness of lipotoxic and proteotoxic ER stress

The dual function of the ER in protein and lipid homeostasis suggests that proteotoxic and lipotoxic stress are interconnected. ER stress triggered by disequilibrium in the lipid bilayer is evidently distinct from proteotoxic ER stress, which is triggered by the accumulation of unfolded or misfolded proteins in the ER lumen. Furthermore, activation of the UPR sensors in lipotoxic stress relies on their transmembrane domains whereas misfolded proteins are sensed by their luminal domains. Both IRE1 α and PERK can be activated via their transmembrane domains upon increases in membrane lipid saturation (Volmer et al., 2013). Interestingly, ATF6 α can be activated by specific sphingolipids, dihydroceramide and dihydrosphingosine, which are recognized by a motif in its transmembrane domain (Tam et al., 2018). However, in spite of these differences, the relationship between lipotoxic ER stress and proteotoxic ER stress is likely bidirectional. SFA accumulation not only disrupts phospholipid homeostasis at the ER membrane, but also impacts on the morphology and integrity of the ER, thereby leading to disturbed ER proteostasis (Borraile et al., 2006). In addition, treatment with the chemical chaperone 4-phenylbutyric acid (4-PBA), which binds ER misfolded proteins, stabilized lipid-induced UPR, suggesting that lipotoxicity induced proteotoxic stress (Pineau et al., 2009). Thus, it is likely that the impairment in proteostasis secondary to lipotoxic ER stress is a consequence of the disruption of normal ER structure and function. Furthermore, lipotoxic UPR induced proteome-remodeling mitigated the detrimental effects of lipotoxic lipid bilayer stress (Thibault et al., 2012). Conversely, proteotoxic UPR activates ER expansion which requires lipid biosynthesis and ER stress impacts cellular lipid homeostasis, as discussed above. The comprehensive signaling outputs of the UPR retain some similarities but also demonstrate some differences between lipotoxic and proteotoxic ER stress. For example, sphingolipid-induced activation of ATF6 α preferentially activated ER lipid biosynthetic genes over ER chaperones and protein-folding genes (Tam et al., 2018). In *Caenorhabditis elegans* models lipid disequilibrium from impaired phosphatidylcholine synthesis resulted in activation of an ER stress response with a transcriptional profile quite distinct from proteotoxic ER stress (Fun & Thibault, 2019). One distinct pathway is autophagy which is activated in an IRE1 α /XBP-1 dependent manner and may be protective against lipotoxic ER stress (Koh, Wang, Beaudoin-Chabot, & Thibault, 2018). Lipotoxic ER stress may also contribute to proteotoxic ER stress by degradation of ER proteins, as recently demonstrated in a *Saccharomyces cerevisiae* lipotoxic ER stress model (Shyu Jr. et al., 2019). Thus lipotoxic and proteotoxic ER stress are interconnected and further studies are needed to understand this relationship especially in hepatocytes in the context of fatty liver disease.

6. Therapeutic potential targeting ER stress and UPR in NAFLD

ER stress is a pathogenic feature of NAFLD (Bechmann et al., 2012; Malhi & Kaufman, 2011); thus targeting the specific UPR signaling pathways to attenuate ER stress and UPR activation may provide opportunities for developing new therapeutic strategies to treat NAFLD. Several compounds have been considered for the treatment of various diseases via their effects on the UPR signaling pathway (Table 1). However,

Table 1
Targeting the UPR in NAFLD

Molecule	Target	Mechanism	Ref.
4-PBA	Chemical chaperone	Stabilize misfolded proteins	(Ozcan et al., 2006)
TUDCA	Chemical chaperone	Stabilize misfolded proteins	(Lebeaupin et al., 2015)
Salubrinal	PERK	Prevent eIF2 α dephosphorylation	(Kuo et al., 2012)
GSK2606414	PERK	PERK-induced JNK activation	(Win et al., 2015)
FGF21	PERK	Reduce eIF2 α -ATF4-CHOP signaling	(Jiang et al., 2014)
STF-083010	IRE1 α	Inhibits RNase activity	(Lebeaupin, Vallee, Rousseau, et al., 2018)
4 μ 8C	IRE1 α	Inhibits RNase activity	(Tufanli et al., 2017)
Toyocamycin	IRE1 α	Block XBP1 processing	(Takahara et al., 2017)

further preclinical development and clinical trials are needed to validate their therapeutic potential in NAFLD.

6.1. PERK-eIF2 α -ATF4 signaling

PERK signaling reduces protein translation by phosphorylated eIF2 α and attenuates ER stress levels by reducing protein misfolding overload. Salubrinal is a small molecule that inhibits dephosphorylation of eIF2 α and protected cells from ER stress-induced apoptosis (Boyce et al., 2005; Hetz, Chevet, & Harding, 2013). It also inhibited free FA-induced-apoptosis and NF κ B activation (Kuo et al., 2012). The PERK inhibitor, GSK2606414, was shown to attenuate palmitic acid-induced JNK activation and cell death in primary mouse hepatocytes (Win et al., 2015). FGF21 was recently identified to play important roles in UPR signaling (Lin et al., 2015; Shimizu, Morimoto, Maruyama, Inoue, & Sato, 2015). Administration of recombinant FGF21 alleviated tunicamycin-induced hepatic steatosis, in parallel with reduction of eIF2 α -ATF4-CHOP signaling (Jiang et al., 2014). Guanabenz is a α 2-adrenergic receptor agonist approved for hypertension. It also binds to GADD34 and selectively inhibits GADD34-mediated dephosphorylation of eIF2 α and exerted a cytoprotective effect against ER stress by prolonging UPR signaling (Tsaytler, Harding, Ron, & Bertolotti, 2011). As optimal eIF2 α phosphorylation is protective in several metabolic pathologies, including β cell failure, guanabenz may be a promising candidate for the treatment of NAFLD.

6.2. IRE1 α signaling

Activated IRE1 α induces processing of XBP1 and RNA degradation through RIDD via its RNase activity. Salicylaldehyde analogs, such as STF-083010 and 4 μ 8C were shown to covalently attach to a lysine residue and to inhibit the RNase activity of IRE1 α (Mimura et al., 2012; Papandreou et al., 2011; Sanches et al., 2014; Volkmann et al., 2011). Many such salicylaldehyde derivatives block both XBP1 processing and RIDD without affecting the kinase activity of IRE1 α (Cross et al., 2012; Sanches et al., 2014; Volkmann et al., 2011). STF-083010 or 4 μ 8C showed improvement of NAFLD in HFD-fed mice (Lebeaupin, Vallee, Rousseau, et al., 2018). Toyocamycin was recently reported to attenuate the activation of XBP1, possibly by inducing a conformational change in IRE1 α (Ri et al., 2012). Toyocamycin ameliorated hepatic steatosis and liver injury caused by HFD-induced NASH (Takahara et al., 2017).

6.3. Chemical chaperons

Chemical chaperones modulate ER stress by attenuating protein misfolding and aggregation and stabilizing folding intermediates. Chemical chaperones reduced ER stress, improved insulin sensitivity and glucose homeostasis, and reversed leptin resistance in the liver of an obese mouse model (Hetz et al., 2013; Ozcan et al., 2009; Ozcan et al., 2006). Tauroursodeoxycholic acid (TUDCA) and 4-PBA are chemical chaperones that have been shown to reduce ER stress by facilitating proper protein folding and trafficking (Henkel, 2018; Vilatoba et al., 2005; Xie et al., 2002). Treatment with 4-PBA improved glucose

tolerance in insulin-resistant patients and TUDCA partially restored insulin sensitivity in liver and muscle, but not adipose tissue in obese patients (Kars et al., 2010; C. Xiao, Giacca, & Lewis, 2011). Mitigating ER stress using these chemical chaperones in mouse models with steatotic livers reduces hepatic lipid accumulation and hepatic fibrogenesis (Jimenez-Castro et al., 2012; Namisaki et al., 2016; U. Ozcan et al., 2006). Unfortunately, the efficacy of these chaperones in NAFLD has been less impressive. Several randomized trials using ursodeoxycholic acid have failed to improve the overall histology in patients with NASH in comparison with placebo (Dufour et al., 2006; Leuschner et al., 2010; Lindor et al., 2004). Whether other chemical chaperones may be effective remains to be determined.

6.4. Additional consideration on the therapeutic modulation of the UPR

BiP is an essential chaperone involved in the activation of PERK and IRE1 α and translocation of ATF6 α . BiP inducer X was identified as a modulator to induce BiP expression in the neural system and kidney (Nakanishi et al., 2013; Prachasilchai et al., 2009). Studies on the use of BiP inducer X in NAFLD remain to be explored. CHOP is another UPR target. Inhibitors of p38 mitogen-activated protein kinase inhibit the phosphorylation of CHOP, which is critical for its function as a transcription factor (X. Z. Wang & Ron, 1996). However, not only is there a shortage of CHOP-specific inhibitors, but there is a lack of research on the effectiveness of CHOP inhibitors in NAFLD. Glucagon-like peptide-1 analogues that are currently used in the treatment of type 2 diabetes reduce hepatic steatosis and insulin resistance in mouse models of fatty liver disease and reduce ER stress and fat accumulation in cultured human hepatocytes (Ding, Saxena, Lin, Gupta, & Anania, 2006; Sharma, Mells, Fu, Saxena, & Anania, 2011). The safety and efficacy of the long acting glucagon-like peptide-1 analogue, liraglutide, has been reported in patients with NASH (Armstrong et al., 2016). However, whether this improvement involves a reduction of ER stress remains to be proven.

7. Conclusions

NASH is a complex disease that is modulated by numerous mechanisms including metabolic, genetic, and environmental factors. Although steatosis is a fundamental characteristic of NAFLD, the specific signaling mechanisms that lead to inflammation and progressive injury in NASH are not completely delineated. ER stress is considered a key factor in steatosis, such that hepatic lipid accumulation is both a cause and a consequence of ER stress, thus creating a positive feedback loop which may promote the development of hepatic steatosis. We further propose that the selective lipotoxic activation or inactivation of UPR sensors and their downstream signaling molecules may play a role in determining the outcomes of isolated steatosis versus progressive NASH. This concept needs further experimental testing to identify which of these signaling pathways offers interesting targets to therapeutically inhibit NASH progression. Lastly, the inter-connectedness of proteotoxic and lipotoxic ER stress is beginning to be defined, as are their unique characteristics, which will have relevance to disease pathogenesis and therapeutic targeting.

Declaration of Competing Interest

The authors declare that there are no conflicts of interest.

Grant Support: This work is partially supported by the NIH grant DK111378 and the Mayo Foundation.

References

- Adachi, Y., Yamamoto, K., Okada, T., Yoshida, H., Harada, A., & Mori, K. (2008). ATF6 is a transcription factor specializing in the regulation of quality control proteins in the endoplasmic reticulum. *Cell Structure and Function* 33, 75–89.
- Aflaki, E., Doddapattar, P., Radovic, B., Povoden, S., Kolb, D., Vujic, N., ... Kratky, D. (2012). C16 ceramide is crucial for triacylglycerol-induced apoptosis in macrophages. *Cell Death & Disease* 3, e280.
- Akazawa, Y., Cazanave, S., Mott, J. L., Elmi, N., Bronk, S. F., Kohno, S., ... Gores, G. J. (2010). Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. *Journal of Hepatology* 52, 586–593.
- Amor, A. J., & Perea, V. (2019). Dyslipidemia in nonalcoholic fatty liver disease. *Current Opinion in Endocrinology, Diabetes, and Obesity* 26, 103–108.
- Ariyama, H., Kono, N., Matsuda, S., Inoue, T., & Arai, H. (2010). Decrease in membrane phospholipid unsaturation induces unfolded protein response. *The Journal of Biological Chemistry* 285, 22027–22035.
- Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., ... Newsome, P. N. (2016). Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 387, 679–690.
- Bechmann, L. P., Hannivoort, R. A., Gerken, G., Hotamisligil, G. S., Trauner, M., & Canbay, A. (2012). The interaction of hepatic lipid and glucose metabolism in liver diseases. *Journal of Hepatology* 56, 952–964.
- Bertolotti, A., Zhang, Y., Hendershot, L. M., Harding, H. P., & Ron, D. (2000). Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. *Nature Cell Biology* 2, 326–332.
- Blais, J. D., Filipenko, V., Bi, M., Harding, H. P., Ron, D., Koumenis, C., ... Bell, J. C. (2004). Activating transcription factor 4 is transcriptionally regulated by hypoxic stress. *Molecular and Cellular Biology* 24, 7469–7482.
- Blond, E., Disse, E., Cuercq, C., Draï, J., Valette, P. J., Laville, M., ... Caussy, C. (2017). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: Do they lead to over-referral? *Diabetologia* 60, 1218–1222.
- Bommiasamy, H., Back, S. H., Fagone, P., Lee, K., Meshinchi, S., Vink, E., ... Brewer, J. W. (2009). ATF6alpha induces XBP1-independent expansion of the endoplasmic reticulum. *Journal of Cell Science* 122, 1626–1636.
- Borradaile, N. M., Han, X., Harp, J. D., Gale, S. E., Ory, D. S., & Schaffer, J. E. (2006). Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. *Journal of Lipid Research* 47, 2726–2737.
- Boyce, M., Bryant, K. F., Jousse, C., Long, K., Harding, H. P., Scheuner, D., ... Yuan, J. (2005). A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. *Science* 307, 935–939.
- Breslow, D. K. (2013). Sphingolipid homeostasis in the endoplasmic reticulum and beyond. *Cold Spring Harbor Perspectives in Biology* 5, a013326.
- Brown, M. S., & Goldstein, J. L. (1997). The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. *Cell* 89, 331–340.
- Bruce, C. R., Risis, S., Babb, J. R., Yang, C., Kowalski, G. M., Selathurai, A., ... Febbraio, M. A. (2012). Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice. *Diabetes* 61, 3148–3155.
- Cao, J., Dai, D. L., Yao, L., Yu, H. H., Ning, B., Zhang, Q., ... Yang, Z. X. (2012). Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK/ATF4/CHOP signaling pathway. *Molecular and Cellular Biochemistry* 364, 115–129.
- Carrara, M., Prisch, F., Nowak, P. R., & Ali, M. M. (2015). Crystal structures reveal transient PERK luminal domain tetramerization in endoplasmic reticulum stress signaling. *The EMBO Journal* 34, 1589–1600.
- Cazanave, S. C., Elmi, N. A., Akazawa, Y., Bronk, S. F., Mott, J. L., & Gores, G. J. (2010). CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. *American Journal of Physiology. Gastrointestinal and Liver Physiology* 299, G236–G243.
- Chaurasia, B., Tippetts, T. S., Mayoral Monibas, R., Liu, J., Li, Y., Wang, L., ... Summers, S. A. (2019). Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. *Science* 365, 386–392.
- Chen, X., Zhang, F., Gong, Q., Cui, A., Zhuo, S., Hu, Z., ... Li, Y. (2016). Hepatic ATF6 increases fatty acid oxidation to attenuate hepatic steatosis in mice through peroxisome proliferator-activated receptor alpha. *Diabetes* 65, 1904–1915.
- Cohen, D. E., & Fisher, E. A. (2013). Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. *Seminars in Liver Disease* 33, 380–388.
- Cross, B. C., Bond, P. J., Sadowski, P. G., Jha, B. K., Zak, J., Goodman, J. M., ... Harding, H. P. (2012). The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. *Proceedings of the National Academy of Sciences of the United States of America* 109, E869–E878.
- DeZwaan-McCabe, D., Sheldon, R. D., Gorecki, M. C., Guo, D. F., Gansemer, E. R., Kaufman, R. J., ... Rutkowski, D. T. (2017). ER Stress Inhibits Liver Fatty Acid Oxidation while Unmitigated Stress Leads to Anorexia-Induced Lipolysis and Both Liver and Kidney Steatosis. *Cell Reports* 19, 1794–1806.
- Ding, X., Saxena, N. K., Lin, S., Gupta, N. A., & Anania, F. A. (2006). Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. *Hepatology* 43, 173–181.
- Dong, X. Y., Tang, S. Q., & Chen, J. D. (2012). Dual functions of Insig proteins in cholesterol homeostasis. *Lipids in Health and Disease* 11, 173.
- Donnelly, K. L., Smith, C. L., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *The Journal of Clinical Investigation* 115, 1343–1351.
- Donnelly, N., Gorman, A. M., Gupta, S., & Samali, A. (2013). The eIF2alpha kinases: Their structures and functions. *Cellular and Molecular Life Sciences* 70, 3493–3511.
- Dufour, J. F., Oneta, C. M., Gonvers, J. J., Bihl, F., Cerny, A., Cereda, J. M., ... Zimmermann, A. (2006). Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. *Clinical Gastroenterology and Hepatology* 4, 1537–1543.
- Eberle, D., Hegarty, B., Bossard, P., Ferre, P., & Foufelle, F. (2004). SREBP transcription factors: Master regulators of lipid homeostasis. *Biochimie* 86, 839–848.
- Epstein, S., Kirkpatrick, C. L., Castillon, G. A., Muniz, M., Riezman, I., David, F. P., ... Riezman, H. (2012). Activation of the unfolded protein response pathway causes ceramide accumulation in yeast and INS-1E insulinoma cells. *Journal of Lipid Research* 53, 412–420.
- Fagone, P., & Jackowski, S. (2009). Membrane phospholipid synthesis and endoplasmic reticulum function. *Journal of Lipid Research* 50(Suppl), S311–S316.
- Foufelle, F., & Ferre, P. (2002). New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: A role for the transcription factor sterol regulatory element binding protein-1c. *The Biochemical Journal* 366, 377–391.
- Fun, X. H., & Thibault, G. (2019 Apr 24). Lipid bilayer stress and proteotoxic stress-induced unfolded protein response deploy divergent transcriptional and non-transcriptional programmes. *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids*. <https://doi.org/10.1016/j.bbalip.2019.04.009> (pii: S1388-1981(19)30062-9, Epub ahead of print).
- Futerman, A. H., & Riezman, H. (2005). The ins and outs of sphingolipid synthesis. *Trends in Cell Biology* 15, 312–318.
- Gimeno, R. E., & Cao, J. (2008). Thematic review series: Glycerolipids. Mammalian glycerol-3-phosphate acyltransferases: New genes for an old activity. *Journal of Lipid Research* 49, 2079–2088.
- Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., ... Brown, H. A. (2015). Biomarkers of NAFLD progression: A lipidomics approach to an epidemic. *Journal of Lipid Research* 56, 722–736.
- Gu, X., Li, K., Laybutt, D. R., He, M. L., Zhao, H. L., Chan, J. C., & Xu, G. (2010). Bip overexpression, but not CHOP inhibition, attenuates fatty-acid-induced endoplasmic reticulum stress and apoptosis in HepG2 liver cells. *Life Sciences* 87, 724–732.
- Han, D., Lerner, A. G., Vande Walle, L., Upton, J. P., Xu, W., Hagen, A., ... Papa, F. R. (2009). IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. *Cell* 138, 562–575.
- Han, J., Back, S. H., Hur, J., Lin, Y. H., Gildersleeve, R., Shan, J., ... Kaufman, R. J. (2013). ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. *Nature Cell Biology* 15, 481–490.
- Han, J., & Kaufman, R. J. (2016). The role of ER stress in lipid metabolism and lipotoxicity. *Journal of Lipid Research* 57, 1329–1338.
- Han, M. S., Park, S. Y., Shinzawa, K., Kim, S., Chung, K. W., Lee, J. H., ... Lee, M. S. (2008). Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. *Journal of Lipid Research* 49, 84–97.
- Han, S., Lone, M. A., Schneider, R., & Chang, A. (2010). Orm1 and Orm2 are conserved endoplasmic reticulum membrane proteins regulating lipid homeostasis and protein quality control. *Proceedings of the National Academy of Sciences of the United States of America* 107, 5851–5856.
- Hannun, Y. A., & Obeid, L. M. (2008). Principles of bioactive lipid signalling: Lessons from sphingolipids. *Nature Reviews. Molecular Cell Biology* 9, 139–150.
- Harding, H. P., Zhang, Y., & Ron, D. (1999). Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. *Nature* 397, 271–274.
- Hassing, H. C., Surendran, R. P., Mooij, H. L., Stroes, E. S., Nieuwdorp, M., & Dallinga-Thie, G. M. (2012). Pathophysiology of hypertriglyceridemia. *Biochimica et Biophysica Acta* 1821, 826–832.
- Haze, K., Yoshida, H., Yanagi, H., Yura, T., & Mori, K. (1999). Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. *Molecular Biology of the Cell* 10, 3787–3799.
- Henkel, A. S. (2018). Unfolded protein response sensors in hepatic lipid metabolism and nonalcoholic fatty liver disease. *Seminars in Liver Disease* 38, 320–332.
- Hetz, C., Chevet, E., & Harding, H. P. (2013). Targeting the unfolded protein response in disease. *Nature Reviews. Drug Discovery* 12, 703–719.
- Hinz, U., Giebel, B., & Campos-Ortega, J. A. (1994). The basic-helix-loop-helix domain of Drosophila lethal of scute protein is sufficient for proneural function and activates neurogenic genes. *Cell* 76, 77–87.
- Hirsova, P., Ibrahim, S. H., Gores, G. J., & Malhi, H. (2016). Lipotoxic lethal and sublethal stress signaling in hepatocytes: Relevance to NASH pathogenesis. *Journal of Lipid Research* 57, 1758–1770.
- Ho, N., Xu, C., & Thibault, G. (2018). From the unfolded protein response to metabolic diseases - lipids under the spotlight. *Journal of Cell Science*, 131.
- Hollien, J., Lin, J. H., Li, H., Stevens, N., Walter, P., & Weissman, J. S. (2009). Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. *The Journal of Cell Biology* 186, 323–331.
- Hollien, J., & Weissman, J. S. (2006). Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. *Science* 313, 104–107.

- Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002). SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. *The Journal of Clinical Investigation* 109, 1125–1131.
- Hu, P., Han, Z., Couvillon, A. D., Kaufman, R. J., & Exton, J. H. (2006). Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. *Molecular and Cellular Biology* 26, 3071–3084.
- Hussain, M. M., Shi, J., & Dreizen, P. (2003). Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. *Journal of Lipid Research* 44, 22–32.
- Ji, C. (2014). New insights into the pathogenesis of alcohol-induced ER stress and liver diseases. *Int J Hepatol* 2014, 513787.
- Jiang, S., Yan, C., Fang, Q. C., Shao, M. L., Zhang, Y. L., Liu, Y., ... Jia, W. P. (2014). Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. *The Journal of Biological Chemistry* 289, 29751–29765.
- Jimenez-Castro, M. B., Elias-Miro, M., Mendes-Braz, M., Lemoine, A., Rimola, A., Rodes, J., ... Peralta, C. (2012). Tauroursodeoxycholic acid affects PPARgamma and TLR4 in Steatotic liver transplantation. *American Journal of Transplantation* 12, 3257–3271.
- Jonikas, M. C., Collins, S. R., Denic, V., Oh, E., Quan, E. M., Schmid, V., ... Schuldiner, M. (2009). Comprehensive characterization of genes required for protein folding in the endoplasmic reticulum. *Science* 323, 1693–1697.
- Joshi-Barve, S., Kirpich, I., Cave, M. C., Marsano, L. S., & McClain, C. J. (2015). Alcoholic, nonalcoholic, and toxicant-associated steatohepatitis: Mechanistic similarities and differences. *Cellular and Molecular Gastroenterology and Hepatology* 1, 356–367.
- Kakazu, E., Mauer, A. S., Yin, M., & Malhi, H. (2016). Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1alpha-dependent manner. *Journal of Lipid Research* 57, 233–245.
- Kakisaka, K., Cazanave, S. C., Fingas, C. D., Guicciardi, M. E., Bronk, S. F., Werneburg, N. W., ... Gores, G. J. (2012). Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. *American Journal of Physiology. Gastrointestinal and Liver Physiology* 302, G77–G84.
- Kammoun, H. L., Chabanon, H., Hainault, I., Luquet, S., Magnan, C., Koike, T., ... Foufelle, F. (2009). GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. *The Journal of Clinical Investigation* 119, 1201–1215.
- Karagöz, G. E., Acosta-Alvarez, D., Nguyen, H. T., Lee, C. P., Chu, F., & Walter, P. (2017). An unfolded protein-induced conformational switch activates mammalian IRE1. *Elife* 6.
- Kars, M., Yang, L., Gregor, M. F., Mohammed, B. S., Pietka, T. A., Finck, B. N., ... Klein, S. (2010). Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. *Diabetes* 59, 1899–1905.
- Koh, J. H., Wang, L., Beaudoin-Chabot, C., & Thibault, G. (2018). Lipid bilayer stress-activated IRE-1 modulates autophagy during endoplasmic reticulum stress. *Journal of Cell Science* 131 (jcs217992).
- Kuo, T. F., Tatsukawa, H., Matsuura, T., Nagatsuma, K., Hirose, S., & Kojima, S. (2012). Free fatty acids induce perglutaminase 2-dependent apoptosis in hepatocytes via ER stress-stimulated PERK pathways. *Journal of Cellular Physiology* 227, 1130–1137.
- Lagace, T. A., & Ridgway, N. D. (2013). The role of phospholipids in the biological activity and structure of the endoplasmic reticulum. *Biochimica et Biophysica Acta* 1833, 2499–2510.
- Lauressergues, E., Bert, E., Duriez, P., Hum, D., Majd, Z., Staels, B., & Cussac, D. (2012). Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation? *Neuropharmacology* 62, 784–796.
- Leamy, A. K., Egnatchik, R. A., Shiota, M., Ivanova, P. T., Myers, D. S., Brown, H. A., & Young, J. D. (2014). Enhanced synthesis of saturated phospholipids is associated with ER stress and lipotoxicity in palmitate treated hepatic cells. *Journal of Lipid Research* 55, 1478–1488.
- Lebeaupein, C., Proics, E., de Bieville, C. H., Rousseau, D., Bonnafous, S., Patouraux, S., ... Bailly-Maitre, B. (2015). ER stress induces NLRP3 inflammasome activation and hepatocyte death. *Cell Death & Disease* 6, e1879.
- Lebeaupein, C., Vallee, D., Hazari, Y., Hetz, C., Chevet, E., & Bailly-Maitre, B. (2018). Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. *Journal of Hepatology* 69, 927–947.
- Lebeaupein, C., Vallee, D., Rousseau, D., Patouraux, S., Bonnafous, S., Adam, G., ... Bailly-Maitre, B. (2018). Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice. *Hepatology* 68, 515–532.
- Lee, A. H., Scapa, E. F., Cohen, D. E., & Glimcher, L. H. (2008). Regulation of hepatic lipogenesis by the transcription factor XBP1. *Science* 320, 1492–1496.
- Lepine, S., Allegood, J. C., Park, M., Dent, P., Milstien, S., & Spiegel, S. (2011). Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy. *Cell Death and Differentiation* 18, 350–361.
- Leuschner, U. F., Lindenthal, B., Herrmann, G., Arnold, J. C., Rossle, M., Cordes, H. J., ... Berg, T. (2010). High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo-controlled trial. *Hepatology* 52, 472–479.
- Li, H., Meng, Q., Xiao, F., Chen, S., Du, Y., Yu, J., ... Guo, F. (2011). ATF4 deficiency protects mice from high-carbohydrate-diet-induced liver steatosis. *The Biochemical Journal* 438, 283–289.
- Li, Z., Agellon, L. B., Allen, T. M., Umeda, M., Jewell, L., Mason, A., & Vance, D. E. (2006). The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. *Cell Metabolism* 3, 321–331.
- Lin, Z., Pan, X., Wu, F., Ye, D., Zhang, Y., Wang, Y., ... Xu, A. (2015). Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. *Circulation* 131, 1861–1871.
- Lindor, K. D., Kowdley, K. V., Heathcote, E. J., Harrison, M. E., Jorgensen, R., Angulo, P., ... Colín, P. (2004). Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. *Hepatology* 39, 770–778.
- Liu, M., Huang, C., Polu, S. R., Schneider, R., & Chang, A. (2012). Regulation of sphingolipid synthesis through Orm1 and Orm2 in yeast. *Journal of Cell Science* 125, 2428–2435.
- Liu, Q., Siloto, R. M., Lehner, R., Stone, S. J., & Weselake, R. J. (2012). Acyl-CoA:diacylglycerol acyltransferase: Molecular biology, biochemistry and biotechnology. *Progress in Lipid Research* 51, 350–377.
- Malhi, H., Barreiro, F. J., Isomoto, H., Bronk, S. F., & Gores, G. J. (2007). Free fatty acids sensitize hepatocytes to TRAIL mediated cytotoxicity. *Gut* 56, 1124–1131.
- Malhi, H., Bronk, S. F., Werneburg, N. W., & Gores, G. J. (2006). Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. *The Journal of Biological Chemistry* 281, 12093–12101.
- Malhi, H., & Gores, G. J. (2008). Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. *Seminars in Liver Disease* 28, 360–369.
- Malhi, H., & Kaufman, R. J. (2011). Endoplasmic reticulum stress in liver disease. *Journal of Hepatology* 54, 795–809.
- Marra, F., & Svegliati-Baroni, G. (2018). Lipotoxicity and the gut-liver axis in NASH pathogenesis. *Journal of Hepatology* 68, 280–295.
- Maruyama, R., Kamoshida, Y., Shimizu, M., Inoue, J., & Sato, R. (2013). ATF6alpha stimulates cholesterologenic gene expression and de novo cholesterol synthesis. *Bioscience, Biotechnology, and Biochemistry* 77, 1734–1738.
- Masouminia, M., Samadzadeh, S., Ebaee, A., French, B. A., Tillman, B., & French, S. W. (2016). Alcoholic steatohepatitis (ASH) causes more UPR-ER stress than non-alcoholic steatohepatitis (NASH). *Experimental and Molecular Pathology* 101, 201–206.
- Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y. T., Cirstea, D., Santo, L., ... Anderson, K. C. (2012). Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. *Blood* 119, 5772–5781.
- Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2018). Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. *Gastroenterology* 155, 282–302 (e288).
- Musso, G., Gambino, R., & Cassader, M. (2009). Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). *Progress in Lipid Research* 48, 1–26.
- Nakanishi, T., Shimazawa, M., Sugitani, S., Kudo, T., Imai, S., Inokuchi, Y., ... Hara, H. (2013). Role of endoplasmic reticulum stress in light-induced photoreceptor degeneration in mice. *Journal of Neurochemistry* 125, 111–124.
- Namisaki, T., Noguchi, R., Moriya, K., Kitade, M., Aihara, Y., Douhara, A., ... Yoshiji, H. (2016). Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. *Journal of Gastroenterology* 51, 162–172.
- Neuschwander-Tetri, B. A. (2010). Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. *Hepatology* 52, 774–788.
- Nishitoh, H. (2012). CHOP is a multifunctional transcription factor in the ER stress response. *Journal of Biochemistry* 151, 217–219.
- Novoa, I., Zeng, H., Harding, H. P., & Ron, D. (2001). Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. *The Journal of Cell Biology* 153, 1011–1022.
- Olofsson, S. O., & Boren, J. (2012). Apolipoprotein B secretory regulation by degradation. *Arteriosclerosis, Thrombosis, and Vascular Biology* 32, 1334–1338.
- Olofsson, S. O., Bostrom, P., Andersson, L., Rutberg, M., Levin, M., Perman, J., & Boren, J. (2008). Triglyceride containing lipid droplets and lipid droplet-associated proteins. *Current Opinion in Lipidology* 19, 441–447.
- Oyadomari, S., Harding, H. P., Zhang, Y., Oyadomari, M., & Ron, D. (2008). Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. *Cell Metabolism* 7, 520–532.
- Ozcan, L., Ergin, A. S., Lu, A., Chung, J., Sarkar, S., Nie, D., ... Ozcan, U. (2009). Endoplasmic reticulum stress plays a central role in development of leptin resistance. *Cell Metabolism* 9, 35–51.
- Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., ... Hotamisligil, G. S. (2006). Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. *Science* 313, 1137–1140.
- Pagadala, M., Kasumov, T., McCullough, A. J., Zein, N. N., & Kirwan, J. P. (2012). Role of ceramides in nonalcoholic fatty liver disease. *Trends in Endocrinology and Metabolism* 23, 365–371.
- Pagliassotti, M. J. (2012). Endoplasmic reticulum stress in nonalcoholic fatty liver disease. *Annual Review of Nutrition* 32, 17–33.
- Papandreou, I., Denko, N. C., Olson, M., Van Melckebeke, H., Lust, S., Tam, A., ... Koong, A. C. (2011). Identification of an IRE1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. *Blood* 117, 1311–1314.
- Pettus, B. J., Chalfant, C. E., & Hannun, Y. A. (2002). Ceramide in apoptosis: An overview and current perspectives. *Biochimica et Biophysica Acta* 1585, 114–125.
- Piccolis, M., Bond, L. M., Kampmann, M., Pulimeno, P., Chitruju, C., Jayson, C. B. K., ... Farese, R. V., Jr. (2019). Probing the global cellular responses to lipotoxicity caused by saturated fatty acids. *Molecular Cell* 74, 32–44 (e38).
- Pineau, L., Colas, J., Dupont, S., Beney, L., Fleurat-Lessard, P., Berjeaud, J. M., ... Ferreira, T. (2009). Lipid-induced ER stress: Synergistic effects of sterols and saturated fatty acids. *Traffic* 10, 673–690.
- Postic, C., & Girard, J. (2008). The role of the lipogenic pathway in the development of hepatic steatosis. *Diabetes & Metabolism* 34, 643–648.
- Prachasilchai, W., Sonoda, H., Yokota-Ikeda, N., Ito, K., Kudo, T., Imaizumi, K., & Ikeda, M. (2009). The protective effect of a newly developed molecular chaperone-inducer against mouse ischemic acute kidney injury. *Journal of Pharmacological Sciences* 109, 311–314.
- Reue, K. (2011). A thematic review series: Lipid droplet storage and metabolism: From yeast to man. *Journal of Lipid Research* 52, 1865–1868.
- Ri, M., Tashiro, E., Oikawa, D., Shinjo, S., Tokuda, M., Yokouchi, Y., ... Iida, S. (2012). Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. *Blood Cancer Journal* 2, e79.
- Ribaux, P. G., & Iynedjian, P. B. (2003). Analysis of the role of protein kinase B (cAKT) in insulin-dependent induction of glucokinase and sterol regulatory element-binding protein 1 (SREBP1) mRNAs in hepatocytes. *The Biochemical Journal* 376, 697–705.

- Rutkowski, D. T., Wu, J., Back, S. H., Callaghan, M. U., Ferris, S. P., Iqbal, J., ... Kaufman, R. J. (2008). UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. *Developmental Cell* 15, 829–840.
- Rutledge, A. C., Su, Q., & Adeli, K. (2010). Apolipoprotein B100 biogenesis: A complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly. *Biochemistry and Cell Biology* 88, 251–267.
- Sakakura, Y., Shimano, H., Sone, H., Takahashi, A., Inoue, N., Toyoshima, H., ... Yamada, N. (2001). Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. *Biochemical and Biophysical Research Communications* 286, 176–183.
- Sanchez, M., Duffy, N. M., Talukdar, M., Thevakumar, N., Chiovitti, D., Canny, M. D., ... Sicheri, F. (2014). Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors. *Nature Communications* 5, 4202.
- Satapathy, S. K., & Sanyal, A. J. (2015). Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. *Seminars in Liver Disease* 35, 221–235.
- Schindler, A. J., & Schekman, R. (2009). In vitro reconstitution of ER-stress induced ATF6 transport in COPII vesicles. *Proceedings of the National Academy of Sciences of the United States of America* 106, 17775–17780.
- Sharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011). GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. *PLoS One* 6, e25269.
- Shimizu, M., Morimoto, H., Maruyama, R., Inoue, J., & Sato, R. (2015). Selective regulation of FGF19 and FGF21 expression by cellular and nutritional stress. *Journal of Nutritional Science and Vitaminology (Tokyo)* 61, 154–160.
- Shyu, P., Jr., Ng, B. S. H., Ho, N., Chaw, R., Seah, Y. L., Marvalim, C., & Thibault, G. (2019). Membrane phospholipid alteration causes chronic ER stress through early degradation of homeostatic ER-resident proteins. *Scientific Reports* 9, 8637.
- Simha, V., & Garg, A. (2006). Lipodystrophy: Lessons in lipid and energy metabolism. *Current Opinion in Lipidology* 17, 162–169.
- So, J. S., Hur, K. Y., Tarrío, M., Ruda, V., Frank-Kamenetsky, M., Fitzgerald, K., ... Lee, A. H. (2012). Silencing of lipid metabolism genes through IRE1alpha-mediated mRNA decay lowers plasma lipids in mice. *Cell Metabolism* 16, 487–499.
- Summers, S. A. (2006). Ceramides in insulin resistance and lipotoxicity. *Progress in Lipid Research* 45, 42–72.
- Takahara, I., Akazawa, Y., Tabuchi, M., Matsuda, K., Miyaaki, H., Kido, Y., ... Nakao, K. (2017). Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice. *PLoS One* 12, e0170591.
- Tam, A. B., Mercado, E. L., Hoffmann, A., & Niwa, M. (2012). ER stress activates NF-kappaB by integrating functions of basal IKK activity, IRE1 and PERK. *PLoS One* 7, e45078.
- Tam, A. B., Roberts, L. S., Chandra, V., Rivera, I. G., Nomura, D. K., Forbes, D. J., & Niwa, M. (2018). The UPR activator ATF6 responds to proteotoxic and lipotoxic stress by distinct mechanisms. *Developmental Cell* 46, 327–343 (e327).
- Thibault, G., Shui, G., Kim, W., McAlister, G. C., Ismail, N., Gygi, S. P., ... Ng, D. T. (2012). The membrane stress response buffers lethal effects of lipid disequilibrium by reprogramming the protein homeostasis network. *Molecular Cell* 48, 16–27.
- Tiwari, S., & Siddiqi, S. A. (2012). Intracellular trafficking and secretion of VLDL. *Arteriosclerosis, Thrombosis, and Vascular Biology* 32, 1079–1086.
- Tsaytler, P., Harding, H. P., Ron, D., & Bertolotti, A. (2011). Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. *Science* 332, 91–94.
- Tufanli, O., Telkoparan Akillilar, P., Acosta-Alvear, D., Kocaturk, B., Onat, U. I., Hamid, S. M., ... Erbay, E. (2017). Targeting IRE1 with small molecules counteracts progression of atherosclerosis. *Proceedings of the National Academy of Sciences of the United States of America* 114, E1395–e1404.
- Upton, J. P., Wang, L., Han, D., Wang, E. S., Huskey, N. E., Lim, L., ... Oakes, S. A. (2012). IRE1alpha cleaves select microRNAs during ER stress to derepress translation of proapoptotic Caspase-2. *Science* 338, 818–822.
- Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H. P., & Ron, D. (2000). Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. *Science* 287, 664–666.
- Usui, M., Yamaguchi, S., Tanji, Y., Tominaga, R., Ishigaki, Y., Fukumoto, M., ... Ishihara, H. (2012). Atf6alpha-null mice are glucose intolerant due to pancreatic beta-cell failure on a high-fat diet but partially resistant to diet-induced insulin resistance. *Metabolism* 61, 1118–1128.
- Vilatoba, M., Eckstein, C., Bilbao, G., Smyth, C. A., Jenkins, S., Thompson, J. A., ... Contreras, J. L. (2005). Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. *Surgery* 138, 342–351.
- Volkman, K., Lucas, J. L., Vuga, D., Wang, X., Brumm, D., Stiles, C., ... Patterson, J. B. (2011). Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. *The Journal of Biological Chemistry* 286, 12743–12755.
- Volmer, R., van der Ploeg, K., & Ron, D. (2013). Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains. *Proceedings of the National Academy of Sciences of the United States of America* 110, 4628–4633.
- Walker, A. K., Jacobs, R. L., Watts, J. L., Rottiers, V., Jiang, K., Finnegan, D. M., ... Naar, A. M. (2011). A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. *Cell* 147, 840–852.
- Walter, P., & Ron, D. (2011). The unfolded protein response: From stress pathway to homeostatic regulation. *Science* 334, 1081–1086.
- Wang, J. M., Qiu, Y., Yang, Z., Kim, H., Qian, Q., Sun, Q., ... Zhang, K. (2018). IRE1alpha prevents hepatic steatosis by processing and promoting the degradation of select microRNAs. *Science Signaling* 11.
- Wang, S., Chen, Z., Lam, V., Han, J., Hassler, J., Finck, B. N., ... Kaufman, R. J. (2012). IRE1alpha-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis. *Cell Metabolism* 16, 473–486.
- Wang, S., & Kaufman, R. J. (2012). The impact of the unfolded protein response on human disease. *The Journal of Cell Biology* 197, 857–867.
- Wang, S., & Kaufman, R. J. (2014). How does protein misfolding in the endoplasmic reticulum affect lipid metabolism in the liver? *Current Opinion in Lipidology* 25, 125–132.
- Wang, X. Z., & Ron, D. (1996). Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP Kinase. *Science* 272, 1347–1349.
- Wang, Y., Zhang, L., Wu, X., Gurley, E. C., Kennedy, E., Hylemon, P. B., ... Zhou, H. (2013). The role of CCAAT enhancer-binding protein homologous protein in human immunodeficiency virus protease-inhibitor-induced hepatic lipotoxicity in mice. *Hepatology* 57, 1005–1016.
- Wei, Y., Wang, D., Topczewski, F., & Pagliassotti, M. J. (2006). Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. *American Journal of Physiology. Endocrinology and Metabolism* 291, E275–E281.
- Wiesner, P., Leidl, K., Boettcher, A., Schmitz, G., & Liebisch, G. (2009). Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. *Journal of Lipid Research* 50, 574–585.
- Win, S., Than, T. A., Le, B. H., Garcia-Ruiz, C., Fernandez-Checa, J. C., & Kaplowitz, N. (2015). Sab (Sh3bp5) dependence of JNK mediated inhibition of mitochondrial respiration in palmitic acid induced hepatocyte lipotoxicity. *Journal of Hepatology* 62, 1367–1374.
- Wu, J., Rutkowski, D. T., Dubois, M., Swathirajan, J., Saunders, T., Wang, J., ... Kaufman, R. J. (2007). ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. *Developmental Cell* 13, 351–364.
- Xia, J. Y., Holland, W. L., Kusminski, C. M., Sun, K., Sharma, A. X., Pearson, M. J., ... Scherer, P. E. (2015). Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. *Cell Metabolism* 22, 266–278.
- Xiao, C., Giacca, A., & Lewis, G. F. (2011). Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and beta-cell dysfunction in humans. *Diabetes* 60, 918–924.
- Xiao, G., Zhang, T., Yu, S., Lee, S., Calabuig-Navarro, V., Yamauchi, J., ... Dong, H. H. (2013). ATF4 protein deficiency protects against high fructose-induced hypertriglyceridemia in mice. *The Journal of Biological Chemistry* 288, 25350–25361.
- Xie, Q., Khaoustov, V. I., Chung, C. C., Sohn, J., Krishnan, B., Lewis, D. E., & Yoffe, B. (2002). Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. *Hepatology* 36, 592–601.
- Yamamoto, K., Sato, T., Matsui, T., Sato, M., Okada, T., Yoshida, H., ... Mori, K. (2007). Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. *Developmental Cell* 13, 365–376.
- Yamamoto, K., Takahara, K., Oyadomari, S., Okada, T., Sato, T., Harada, A., & Mori, K. (2010). Induction of liver steatosis and lipid droplet formation in ATF6alpha-knockout mice burdened with pharmacological endoplasmic reticulum stress. *Molecular Biology of the Cell* 21, 2975–2986.
- Yang, G., Badeanlou, L., Bielawski, J., Roberts, A. J., Hannun, Y. A., & Samad, F. (2009). Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. *American Journal of Physiology. Endocrinology and Metabolism* 297, E211–E224.
- Yang, L., Calay, E. S., Fan, J., Arduini, A., Kunz, R. C., Gygi, S. P., ... Hotamisligil, G. S. (2015). METABOLISM. S-Nitrosylation links obesity-associated inflammation to endoplasmic reticulum dysfunction. *Science* 349, 500–506.
- Yokoyama, C., Wang, X., Briggs, M. R., Admon, A., Wu, J., Hua, X., ... Brown, M. S. (1993). SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. *Cell* 75, 187–197.
- Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., & Mori, K. (2001). XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. *Cell* 107, 881–891.
- Younossi, Z., Tacke, F., Arrese, M., Sharma, B. C., Mostafa, I., Bugianesi, E., ... Vos, M. B. (2019 Jun). Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Hepatology* 69(6), 2672–2682. <https://doi.org/10.1002/hep.30251>
- Zeng, L., Lu, M., Mori, K., Luo, S., Lee, A. S., Zhu, Y., & Shyy, J. Y. (2004). ATF6 modulates SREBP2-mediated lipogenesis. *The EMBO Journal* 23, 950–958.
- Zhang, K., Wang, S., Malhotra, J., Hassler, J. R., Back, S. H., Wang, G., ... Kaufman, R. J. (2011). The unfolded protein response transducer IRE1alpha prevents ER stress-induced hepatic steatosis. *The EMBO Journal* 30, 1357–1375.
- Zhou, H., & Liu, R. (2014). ER stress and hepatic lipid metabolism. *Frontiers in Genetics* 5, 112.